Loading clinical trials...
Loading clinical trials...
Treatment Efficacy and Safety of 12 Weeks of Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without Baseline NS5A Resistance-associated Variants (DARING)
Conditions
Interventions
daclatasvir
asunaprevir
+1 more
Locations
1
Taiwan
Kaohsiung Medical Universsity
Kaohsiung City, Taiwan
Start Date
November 1, 2016
Primary Completion Date
April 1, 2018
Completion Date
April 1, 2018
Last Updated
January 9, 2019
NCT06953479
NCT03135886
NCT05968573
NCT05042544
NCT05870969
NCT05361603
Lead Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions